Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Microbiol Immunol Infect ; 56(4): 739-746, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37055257

ABSTRACT

BACKGROUND: To investigate the associations between extrahepatic manifestations, autoantibodies, and viremia in patients with hepatitis C virus (HCV) infection. METHODS: This cross-sectional study recruited patients with HCV infection from the outpatient department of a tertiary medical center in Northern Taiwan between January 2017 and August 2019. Autoantibody profiles and the clinical parameters of HCV infection were evaluated using laboratory tests, and a questionnaire was used to record extrahepatic manifestations. HCV infection status, including inactive HCV infection, active hepatitis, and cirrhosis, was defined according to abdominal ultrasonography findings and alanine transaminase levels. RESULTS: A total of 77 patients with HCV were recruited, with 19.5% and 16.9% of patients, respectively, presenting with arthritis and dry eyes. Autoantibody screening revealed rheumatoid factor (RF), antinuclear antibody (ANA), anti-Ro antibody, and anti-La antibody positivity in 20.8%, 23.4%, 13.0%, and 2.6% of the patients, respectively. The presence of RF was associated with arthritis, whereas the presence of ANA was associated with dry eyes but not dry mouth. Active hepatitis and HCV-related cirrhosis were associated with viremia, but not autoantibody profiles. CONCLUSION: In this single-center study, the prevalence of extrahepatic manifestations and autoantibodies did not differ in patients stratified by the HCV infection status. Rheumatic manifestations were associated with the presence of autoantibodies but not with viremia.


Subject(s)
Arthritis , Hepatitis C, Chronic , Hepatitis C , Humans , Autoantibodies , Hepacivirus , Cross-Sectional Studies , Hepatitis C/complications , Hepatitis C/epidemiology , Rheumatoid Factor , Arthritis/complications , Liver Cirrhosis/complications , Hepatitis C, Chronic/complications
2.
Biomedicines ; 10(7)2022 Jul 18.
Article in English | MEDLINE | ID: mdl-35885030

ABSTRACT

Patients with rheumatoid arthritis (RA), a chronic inflammatory joint disorder, may not respond adequately to current RA treatments. Mesenchymal stem cells (MSCs) elicit several immunomodulatory and anti-inflammatory effects and, thus, have therapeutic potential. Specifically, adipose-derived stem cell (ADSC)-based RA therapy may have considerable potency in modulating the immune response, and human adipose tissue is abundant and easy to obtain. Paracrine factors, such as exosomes (Exos), contribute to ADSCs' immunomodulatory function. ADSC-Exo-based treatment can reproduce ADSCs' immunomodulatory function and overcome the limitations of traditional cell therapy. ADSC-Exos combined with current drug therapies may provide improved therapeutic effects. Using ADSC-Exos, instead of ADSCs, to treat RA may be a promising cell-free treatment strategy. This review summarizes the current knowledge of medical therapies, ADSC-based therapy, and ADSC-Exos for RA and discusses the anti-inflammatory properties of ADSCs and ADSC-Exos. Finally, this review highlights the expanding role and potential immunomodulatory activity of ADSC-Exos in patients with RA.

3.
BMC Pulm Med ; 20(1): 232, 2020 Aug 31.
Article in English | MEDLINE | ID: mdl-32867745

ABSTRACT

BACKGROUND: A study of latent tuberculosis infection (LTBI) burden by chest roentgenography (CXR) with reference to interferon-gamma release assay (IGRA) is still lacking in rheumatic patients of an intermediate tuberculosis burden area. METHODS: We retrospectively reviewed clinical data of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) receiving LTBI screening for biologics from Jan 2013 to April 2014. RESULTS: A total of 238 rheumatic patients who underwent LTBI screening were included in this study, of whom 46 (19.3%) had positive IGRA tests, 178 (74.8%) had negative results, and 14 (5.9%) had indeterminate results. Radiological findings suggesting healed tuberculosis (CXR-old-TB) were found in 18.1% of all patients, 23.9% in the IGRA -positive patients vs 16.9% in the IGRA-negative patients (OR 1.55 95% CI: 0.71-3.39, p = 0.27). Forty (40/46, 87.0%) IGRA-positive patients received isoniazid prophylaxis and 77.5% of them finished treatment. Six patients developed adverse effects of isoniazid treatment, resulting in an overall number needed to harm (NNH) of 6.7 (40/6). IGRA-non-positive patients with old TB-suggestive CXR comprised 13.4% (32/238) of all our rheumatic patients, and one of them developed pulmonary tuberculosis within one year after screening. CONCLUSIONS: LTBI disease burden in rheumatic patients is substantial according to the estimation of CXR and IGRA screening. Correlation between CXR and IGRA is not significant in rheumatic patients, which implies their complementary roles. IGRA-non-positive patients with old TB-suggestive CXR comprise a significant portion in rheumatic patients and merit cautious follow-up by rheumatologists, tuberculosis specialists, and pulmonologists.


Subject(s)
Antirheumatic Agents/adverse effects , Biological Products/adverse effects , Latent Tuberculosis/diagnostic imaging , Latent Tuberculosis/etiology , Radiography, Thoracic , Adult , Aged , Antirheumatic Agents/therapeutic use , Antitubercular Agents/adverse effects , Arthritis, Psoriatic/drug therapy , Arthritis, Rheumatoid/drug therapy , Biological Products/therapeutic use , Female , Humans , Interferon-gamma Release Tests , Isoniazid/adverse effects , Latent Tuberculosis/diagnosis , Latent Tuberculosis/drug therapy , Male , Middle Aged , Retrospective Studies , Spondylitis, Ankylosing/drug therapy , Tuberculin Test/methods
4.
J Microbiol Immunol Infect ; 48(5): 477-82, 2015 Oct.
Article in English | MEDLINE | ID: mdl-24560699

ABSTRACT

BACKGROUND: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and Churg-Strauss syndrome (CSS), comprises a group of diseases with significant morbidity and mortality. The incidence and relative frequency of GPA/MPA/CSS are different all over the world. The epidemiology of AAV in Taiwan is still not clear. METHODS: The current study aimed to provide a population-based estimate of the annual incidence of GPA using the Taiwan National Health Insurance (NHI) research database and a single hospital-based estimate of the relative frequency of AAV in Taiwan. RESULTS: The annual incidence of GPA in Taiwan was 0.37 per million patient-years (95% Poisson rate confidence interval: 0.30-0.45) from 1997 to 2008, according to the NHI database. In our hospital, 24 patients were newly diagnosed with AAV between 2003 and 2011, including eight patients with GPA, 14 with MPA, and two with CSS. The ratio of the number of patients with GPA to that of MPA was 0.57. CONCLUSION: The current results provide an estimate of the annual incidence of GPA and the relative frequency of AAV in the Chinese Han community in Taiwan. Such geoepidemiology information may help illuminate the interaction between ethnic background and environment in these autoimmune diseases.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/immunology , Churg-Strauss Syndrome/epidemiology , Churg-Strauss Syndrome/pathology , Granulomatosis with Polyangiitis/epidemiology , Granulomatosis with Polyangiitis/pathology , Microscopic Polyangiitis/epidemiology , Microscopic Polyangiitis/pathology , Adult , Aged , Aged, 80 and over , Churg-Strauss Syndrome/etiology , Female , Granulomatosis with Polyangiitis/etiology , Hospitals , Humans , Incidence , Male , Microscopic Polyangiitis/etiology , Middle Aged , National Health Programs , Taiwan/epidemiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...